CDP 870 - 3rd generation anti-TNF? therapy  for RA and Crohn’s

• Anti-TNF? treatment market

  • 2001: ~ $1.5bn (Enbrel, Remicade)

• CDP 870: PEG-Ab fragment

  • very high affinity

• 4-wkly dosing

• Proprietary E.coli manufacture

  • cost 5-10% of whole Ab
  • contract with major manufacturer

Previous slide

Next slide

Back to first slide

View graphic version